BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Graham RP. Fibrolamellar Carcinoma: What Is New and Why It Matters. Surg Pathol Clin. 2018;11:377-387. [PMID: 29751881 DOI: 10.1016/j.path.2018.02.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Wolfson B, Franks SE, Hodge JW. Stay on Target: Reengaging Cancer Vaccines in Combination Immunotherapy. Vaccines (Basel) 2021;9:509. [PMID: 34063388 DOI: 10.3390/vaccines9050509] [Reference Citation Analysis]
2 Vij M, Calderaro J. Pathologic and molecular features of hepatocellular carcinoma: An update. World J Hepatol 2021; 13(4): 393-410 [PMID: 33959223 DOI: 10.4254/wjh.v13.i4.393] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Wolosz D, Walczak A, Szparecki G, Dwojak M, Winiarska M, Wolinska E, Gornicka B. Deleted in Liver Cancer 2 (DLC2) protein expression in hepatocellular carcinoma. Eur J Histochem 2019;63. [PMID: 30827083 DOI: 10.4081/ejh.2019.2981] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
4 Vyas M, Hechtman JF, Zhang Y, Benayed R, Yavas A, Askan G, Shia J, Klimstra DS, Basturk O. DNAJB1-PRKACA fusions occur in oncocytic pancreatic and biliary neoplasms and are not specific for fibrolamellar hepatocellular carcinoma. Mod Pathol. 2020;33:648-656. [PMID: 31676785 DOI: 10.1038/s41379-019-0398-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
5 Abou-Alfa GK, Mayer R, Venook AP, O'Neill AF, Beg MS, LaQuaglia M, Kingham PT, Kobos R, Basturk O, Brennan C, Yopp A, Harding JJ, Leong S, Crown J, Hoti E, Leonard G, Ly M, Bradley M, Valentino E, Markowitz D, Zukiwski A, Ren K, Gordan JD. Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma. Oncologist 2020;25:e1837-45. [PMID: 32154962 DOI: 10.1634/theoncologist.2020-0093] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
6 Dinh TA, Utria AF, Barry KC, Ma R, Abou-Alfa GK, Gordan JD, Jaffee EM, Scott JD, Zucman-Rossi J, O'Neill AF, Furth ME, Sethupathy P. A framework for fibrolamellar carcinoma research and clinical trials. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35190728 DOI: 10.1038/s41575-022-00580-3] [Reference Citation Analysis]
7 Agnello F, Rabiolo L, Midiri F, Lo Re G, Grassedonio E, La Grutta L, Buscemi S, Agrusa A, Galia M. Focal hepatic intrinsically hyperattenuating lesions at unenhanced CT: Not always calcifications. Clin Imaging 2021;80:304-14. [PMID: 34482241 DOI: 10.1016/j.clinimag.2021.08.020] [Reference Citation Analysis]
8 Lamarca A, Frizziero M, Fulton A, McNamara MG, Filobbos R, Hubner RA, Wardell S, Valle JW. Fibrolamellar carcinoma: Challenging the challenge. Eur J Cancer 2020;137:144-7. [PMID: 32768872 DOI: 10.1016/j.ejca.2020.06.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Ahmed A, Ata F, Gaber M, Petkar M, Mahfouz A, Schirmacher P, Musa S, Hashim A. Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review. Current Problems in Cancer 2022. [DOI: 10.1016/j.currproblcancer.2022.100847] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Ahmed A, Ata F, Gaber M, Petkar M, Mahfouz A, Schirmacher P, Musa S, Hashim A. Refractory Hyperammonemic encephalopathy in Fibrolamellar hepatocellular carcinoma, a case report and literature review. Current Problems in Cancer: Case Reports 2022. [DOI: 10.1016/j.cpccr.2022.100141] [Reference Citation Analysis]
11 Wege H, Schulze K, von Felden J, Calderaro J, Reig M; rare liver tumors working group of the European Reference Network on Hepatological Diseases (ERN RARE-LIVER). Rare variants of primary liver cancer: Fibrolamellar, combined, and sarcomatoid hepatocellular carcinomas. Eur J Med Genet 2021;64:104313. [PMID: 34418585 DOI: 10.1016/j.ejmg.2021.104313] [Reference Citation Analysis]